发布求助
文献互助 智能选刊 最新文献

Current Opinion in Endocrinology & Diabetes and Obesity最新文献

筛选
英文 中文
Insight into the potential of bone turnover biomarkers: integration in the management of osteoporosis and chronic kidney disease-associated osteoporosis. 洞察骨转换生物标志物的潜力：整合骨质疏松症和慢性肾病相关骨质疏松症的管理。
IF 2.6 3区 医学
Current Opinion in Endocrinology & Diabetes and Obesity Pub Date : 2024-08-01 Epub Date: 2024-05-27 DOI: 10.1097/MED.0000000000000869
Pauline Brouwers, Antoine Bouquegneau, Etienne Cavalier
{"title":"Insight into the potential of bone turnover biomarkers: integration in the management of osteoporosis and chronic kidney disease-associated osteoporosis.","authors":"Pauline Brouwers, Antoine Bouquegneau, Etienne Cavalier","doi":"10.1097/MED.0000000000000869","DOIUrl":"10.1097/MED.0000000000000869","url":null,"abstract":"<p><strong>Purpose of review: </strong>Disturbances in mineral and bone metabolism occurring in osteoporosis and chronic kidney disease-associated osteoporosis place patients at high risk of fracture making these conditions a major public health concern. Due to the limited use of bone histomorphometry in clinical practice, the gold standard for assessing bone turnover, extensive efforts have been made to identify bone turnover markers (BTMs) as noninvasive surrogates. Since the identification of certain commonly used markers several decades ago, considerable experience has been acquired regarding their clinical utility in such bone disorders.</p><p><strong>Recent findings: </strong>Mounting evidence suggested that BTMs represent a simple, low-risk, rapid and convenient way to obtain data on the skeletal health and that they may be useful in guiding therapeutic choices and monitoring the response to treatment.</p><p><strong>Summary: </strong>BTMs could provide clinicians with useful information, independent from, and often complementary to bone mineral density (BMD) measurements. They have proven valuable for monitoring the effectiveness of osteoporosis therapy, as well as promising for discriminating low and high turnover states. Improved performance is observed when BTMs are combined, which may be useful for selecting treatments for chronic kidney disease-bone mineral disorders (CKD-MBD).</p>","PeriodicalId":10964,"journal":{"name":"Current Opinion in Endocrinology & Diabetes and Obesity","volume":" ","pages":"149-156"},"PeriodicalIF":2.6,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141158139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recent advances in fibroblast growth factor 23-related hypophosphatemic disorders. 成纤维细胞生长因子 23 相关低磷血症的最新进展。
IF 2.6 3区 医学
Current Opinion in Endocrinology & Diabetes and Obesity Pub Date : 2024-08-01 Epub Date: 2024-04-30 DOI: 10.1097/MED.0000000000000866
Yuichi Takashi, Daiji Kawanami, Seiji Fukumoto
{"title":"Recent advances in fibroblast growth factor 23-related hypophosphatemic disorders.","authors":"Yuichi Takashi, Daiji Kawanami, Seiji Fukumoto","doi":"10.1097/MED.0000000000000866","DOIUrl":"10.1097/MED.0000000000000866","url":null,"abstract":"<p><strong>Purpose of review: </strong>Fibroblast growth factor 23 (FGF23) is a hormone to reduce blood phosphate concentration. Excessive actions of FGF23 induce FGF23-related hypophosphatemic disorders, such as X-linked hypophosphatemic rickets (XLH) and tumor-induced osteomalacia (TIO). We will summarize recent advances in the diagnosis and treatment of FGF23-related hypophosphatemic disorders.</p><p><strong>Recent findings: </strong>The measurement of blood FGF23 is useful to make a diagnosis of FGF23-related hypophosphatemic disorders. It was reported that many patients with FGF23-related hypophosphatemic disorders, especially TIO, were misdiagnosed, therefore, it is necessary to enhance the awareness of these diseases. A novel method to inhibit excessive actions of FGF23 by a human monoclonal antibody for FGF23, burosumab, has been approved in several countries. In more long-term observation than clinical trials, burosumab has also been shown to improve biochemical abnormalities and symptoms of rickets/osteomalacia. Following these advances, several registries and consensus recommendations on FGF23-related hypophosphatemic disorders, especially XLH, have been established in each country or region.</p><p><strong>Summary: </strong>Further long-term effects of burosumab and the precise mechanism of FGF23 overproduction in patients with FGF23-related hypophosphatemic disorders need to be clarified in the future studies.</p>","PeriodicalId":10964,"journal":{"name":"Current Opinion in Endocrinology & Diabetes and Obesity","volume":" ","pages":"170-175"},"PeriodicalIF":2.6,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140853015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Gut motility and hormone changes after bariatric procedures. 减肥手术后肠道蠕动和激素的变化。
IF 3.2 3区 医学
Current Opinion in Endocrinology & Diabetes and Obesity Pub Date : 2024-06-01 Epub Date: 2024-03-27 DOI: 10.1097/MED.0000000000000860
Khushboo Gala, Wissam Ghusn, Barham K Abu Dayyeh
{"title":"Gut motility and hormone changes after bariatric procedures.","authors":"Khushboo Gala, Wissam Ghusn, Barham K Abu Dayyeh","doi":"10.1097/MED.0000000000000860","DOIUrl":"10.1097/MED.0000000000000860","url":null,"abstract":"<p><strong>Purpose of review: </strong>Metabolic and bariatric surgery (MBS) and endoscopic bariatric therapies (EBT) are being increasingly utilized for the management of obesity. They work through multiple mechanisms, including restriction, malabsorption, and changes in the gastrointestinal hormonal and motility.</p><p><strong>Recent findings: </strong>Roux-en-Y gastric bypass (RYGB) and laparoscopic sleeve gastrectomy (LSG) cause decrease in leptin, increase in GLP-1 and PYY, and variable changes in ghrelin (generally thought to decrease). RYGB and LSG lead to rapid gastric emptying, increase in small bowel motility, and possible decrease in colonic motility. Endoscopic sleeve gastroplasty (ESG) causes decrease in leptin and increase in GLP-1, ghrelin, and PYY; and delayed gastric motility.</p><p><strong>Summary: </strong>Understanding mechanisms of action for MBS and EBT is critical for optimal care of patients and will help in further refinement of these interventions.</p>","PeriodicalId":10964,"journal":{"name":"Current Opinion in Endocrinology & Diabetes and Obesity","volume":" ","pages":"131-137"},"PeriodicalIF":3.2,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140293080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Potassium-competitive acid blockers and acid-related disorders. 钾竞争性酸阻滞剂与酸相关疾病。
IF 2.6 3区 医学
Current Opinion in Endocrinology & Diabetes and Obesity Pub Date : 2024-06-01 Epub Date: 2024-03-14 DOI: 10.1097/MED.0000000000000858
Kevin Z Huang, H Christian Weber
{"title":"Potassium-competitive acid blockers and acid-related disorders.","authors":"Kevin Z Huang, H Christian Weber","doi":"10.1097/MED.0000000000000858","DOIUrl":"10.1097/MED.0000000000000858","url":null,"abstract":"<p><strong>Purpose of review: </strong>Potassium-competitive acid blockers (PCABs) represent a new class of compounds for the treatment of acid-related disorders. Recent FDA approval of the PCAB vonoprazan for erosive esophagitis has started an important new approach to acid-related disorders.</p><p><strong>Recent findings: </strong>Compared to conventional proton pump inhibitors (PPIs), PCABs provide more rapid, potent, and sustained suppression of gastric acid with faster and more durable symptom relief. Studies have demonstrated the efficacy of PCABs for erosive esophagitis, nonerosive reflux disease, and peptic ulcer disease including H. pylori. However, the PCAB vonoprazan was only approved in the US as part of combination therapy for eradication of H. pylori. Clinical trials have now demonstrated noninferiority of vonoprazan to lansoprazole for treatment of erosive esophagitis, particularly noting superiority of vonoprazan in patients with severe esophagitis resulting in FDA approval of vonoprazan for treatment of erosive esophagitis. Emerging data suggests a possible utility of vonoprazan for PPI-resistant gastroesophageal reflux disease (GERD) and on-demand therapy for nonerosive reflux disease. Vonoprazan is generally well tolerated but long-term safety data is not well established.</p><p><strong>Summary: </strong>The PCAB vonoprazan is a newly FDA approved treatment option for erosive esophagitis. Its possible role in PPI-resistant GERD and nonerosive reflux disease warrants further investigation.</p>","PeriodicalId":10964,"journal":{"name":"Current Opinion in Endocrinology & Diabetes and Obesity","volume":" ","pages":"107-114"},"PeriodicalIF":2.6,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140119033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Gut hormones and appetite regulation. 肠道激素与食欲调节
IF 3.2 3区 医学
Current Opinion in Endocrinology & Diabetes and Obesity Pub Date : 2024-06-01 Epub Date: 2024-03-21 DOI: 10.1097/MED.0000000000000859
So-Hyeon Hong, Kyung Mook Choi
{"title":"Gut hormones and appetite regulation.","authors":"So-Hyeon Hong, Kyung Mook Choi","doi":"10.1097/MED.0000000000000859","DOIUrl":"10.1097/MED.0000000000000859","url":null,"abstract":"<p><strong>Purpose of review: </strong>Various gut hormones interact with the brain through delicate communication, thereby influencing appetite and subsequent changes in body weight. This review summarizes the effects of gut hormones on appetite, with a focus on recent research.</p><p><strong>Recent findings: </strong>Ghrelin is known as an orexigenic hormone, whereas glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), cholecystokinin (CCK), postprandial peptide YY (PYY), and oxyntomodulin (OXM) are known as anorexigenic hormones. Recent human studies have revealed that gut hormones act differently in various systems, including adipose tissue, beyond appetite and energy intake, and even involve in high-order thinking. Environmental factors including meal schedule, food contents and quality, type of exercise, and sleep deprivation also play a role in the influence of gut hormone on appetite, weight change, and obesity. Recently published studies have shown that retatrutide, a triple-agonist of GLP-1, GIP, and glucagon receptor, and orforglipron, a GLP-1 receptor partial agonist, are effective in weight loss and improving various metabolic parameters associated with obesity.</p><p><strong>Summary: </strong>Various gut hormones influence appetite, and several drugs targeting these receptors have been reported to exert positive effects on weight loss in humans. Given that diverse dietary and environmental factors affect the actions of gut hormones and appetite, there is a need for integrated and largescale long-term studies in this field.</p>","PeriodicalId":10964,"journal":{"name":"Current Opinion in Endocrinology & Diabetes and Obesity","volume":" ","pages":"115-121"},"PeriodicalIF":3.2,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140174020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Editorial overview. 编辑综述。
IF 3.2 3区 医学
Current Opinion in Endocrinology & Diabetes and Obesity Pub Date : 2024-06-01 Epub Date: 2024-04-25 DOI: 10.1097/MED.0000000000000861
Horst Christian Weber
{"title":"Editorial overview.","authors":"Horst Christian Weber","doi":"10.1097/MED.0000000000000861","DOIUrl":"https://doi.org/10.1097/MED.0000000000000861","url":null,"abstract":"","PeriodicalId":10964,"journal":{"name":"Current Opinion in Endocrinology & Diabetes and Obesity","volume":"31 3","pages":"105-106"},"PeriodicalIF":3.2,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140847240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Editorial introduction. 编辑介绍。
IF 3.2 3区 医学
Current Opinion in Endocrinology & Diabetes and Obesity Pub Date : 2024-06-01 Epub Date: 2024-04-25 DOI: 10.1097/MED.0000000000000862
{"title":"Editorial introduction.","authors":"","doi":"10.1097/MED.0000000000000862","DOIUrl":"10.1097/MED.0000000000000862","url":null,"abstract":"","PeriodicalId":10964,"journal":{"name":"Current Opinion in Endocrinology & Diabetes and Obesity","volume":"31 3","pages":"v"},"PeriodicalIF":3.2,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140853531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The interaction between gut microbiome and bone health. 肠道微生物群与骨骼健康之间的相互作用。
IF 3.2 3区 医学
Current Opinion in Endocrinology & Diabetes and Obesity Pub Date : 2024-04-09 DOI: 10.1097/med.0000000000000863
Francesco Inchingolo, Angelo Michele Inchingolo, Fabio Piras, Laura Ferrante, Antonio Mancini, Andrea Palermo, Alessio Danilo Inchingolo, Gianna Dipalma
{"title":"The interaction between gut microbiome and bone health.","authors":"Francesco Inchingolo, Angelo Michele Inchingolo, Fabio Piras, Laura Ferrante, Antonio Mancini, Andrea Palermo, Alessio Danilo Inchingolo, Gianna Dipalma","doi":"10.1097/med.0000000000000863","DOIUrl":"https://doi.org/10.1097/med.0000000000000863","url":null,"abstract":"This review critically examines interconnected health domains like gut microbiome, bone health, interleukins, chronic periodontitis, and coronavirus disease 2019 (COVID-19), offering insights into fundamental mechanisms and clinical implications, contributing significantly to healthcare and biomedical research.","PeriodicalId":10964,"journal":{"name":"Current Opinion in Endocrinology & Diabetes and Obesity","volume":"46 1","pages":""},"PeriodicalIF":3.2,"publicationDate":"2024-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140577027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Health economics of detection and treatment of children with familial hypercholesterolemia: to screen or not to screen is no longer the question. 家族性高胆固醇血症儿童检测和治疗的卫生经济学:筛查或不筛查已不再是问题。
IF 3.2 3区 医学
Current Opinion in Endocrinology & Diabetes and Obesity Pub Date : 2024-04-01 Epub Date: 2023-11-20 DOI: 10.1097/MED.0000000000000844
Clara Marquina, Jedidiah I Morton, Zanfina Ademi
{"title":"Health economics of detection and treatment of children with familial hypercholesterolemia: to screen or not to screen is no longer the question.","authors":"Clara Marquina, Jedidiah I Morton, Zanfina Ademi","doi":"10.1097/MED.0000000000000844","DOIUrl":"10.1097/MED.0000000000000844","url":null,"abstract":"<p><strong>Purpose of review: </strong>Heterozygous familial hypercholesterolemia (HeFH) is one of the most common monogenic disorders and is safely treatable with lipid-lowering medication. However, most individuals with HeFH remain untreated and undetected, especially in paediatric populations where the potential for long-term therapeutic benefit is higher. Here, we review the recent literature on health economic outcomes for the detection and management of FH in children.</p><p><strong>Recent findings: </strong>A targeted literature review identified eight studies evaluating detection and management strategies for paediatric FH populations in the last 25 years. Most studies conducted modelled cost-effectiveness analyses to understand the long-term impact of these strategies on health outcomes and the financial impact on the healthcare system. All studies reported that detection and management of HeFH in paediatric populations was cost-effective, regardless of the age of the children. However, cost-effectiveness varied depending on the method of case ascertainment - targeted screening was generally cheaper overall, but less effective, than whole-of-population screening, although both methods were generally cost-effective.</p><p><strong>Summary: </strong>Detection and management of HeFH in paediatric populations is a cost-effective way to significantly lower the burden of disease later in life for these individuals. These strategies should be implemented across healthcare systems.</p>","PeriodicalId":10964,"journal":{"name":"Current Opinion in Endocrinology & Diabetes and Obesity","volume":" ","pages":"84-89"},"PeriodicalIF":3.2,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138175867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Addressing genetic and environmental sources of cardiometabolic disease. 解决心脏代谢疾病的遗传和环境来源。
IF 3.2 3区 医学
Current Opinion in Endocrinology & Diabetes and Obesity Pub Date : 2024-04-01 Epub Date: 2024-02-29 DOI: 10.1097/MED.0000000000000855
Gerald F Watts, Dick C Chan
{"title":"Addressing genetic and environmental sources of cardiometabolic disease.","authors":"Gerald F Watts, Dick C Chan","doi":"10.1097/MED.0000000000000855","DOIUrl":"10.1097/MED.0000000000000855","url":null,"abstract":"","PeriodicalId":10964,"journal":{"name":"Current Opinion in Endocrinology & Diabetes and Obesity","volume":"31 2","pages":"67-69"},"PeriodicalIF":3.2,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139971320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信